© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Mersana Therapeutics, Inc. (MRSN) stock surged +5.33%, trading at $1.58 on NASDAQ, up from the previous close of $1.50. The stock opened at $1.47, fluctuating between $1.45 and $1.58 in the recent session.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Employees | 123 |
Beta | 1.465 |
Sales or Revenue | $36.86M |
5Y Sales Change% | -0.31% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Mersana Therapeutics, Inc. (NASDAQ: MRSN) stock price is $1.58 in the last trading session. During the trading session, MRSN stock reached the peak price of $1.58 while $1.45 was the lowest point it dropped to. The percentage change in MRSN stock occurred in the recent session was 5.33% while the dollar amount for the price change in MRSN stock was $0.08.
The NASDAQ listed MRSN is part of Biotechnology industry that operates in the broader Healthcare sector. Mersana Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Anna Protopapas M.B.A.
Pres, Chief Executive Officer & Director
Mr. Brian C. DeSchuytner
Senior Vice President & Chief Financial Officer
Dr. Tushar Misra Ph.D.
SVice President & Chief Manufacturing Officer
Mr. Chuck Miller
Senior Vice President of Regulatory Affairs
Dr. Timothy B. Lowinger Ph.D.
Senior Vice President, Chief Science & Technology Officer
Ms. Alejandra Veronica Carvajal J.D.
SVice President, Sec. & Chief Legal Officer
Dr. Arvin Yang M.D., Ph.D.
Senior Vice President & Chief Medical Officer
Mr. Mikhail Papisov Ph.D.
Co-Founder
Mr. Ashish Mandelia
Vice President, Controller & Principal Accounting Officer
Mr. Jason Fredette
Senior Vice President of Investor Relations & Corporation Communications
Ms. Carla Poulson
Senior Vice President & Chief People Officer
MRSN's closing price is 48.36% higher than its 52-week low of $1.07 where as its distance from 52-week high of $6.28 is -74.84%.
Number of MRSN employees currently stands at 123.
Official Website of MRSN is: https://www.mersana.com
MRSN could be contacted at phone 617 498 0020 and can also be accessed through its website. MRSN operates from 840 Memorial Drive, Cambridge, MA 02139, United States.
MRSN stock volume for the day was 458.07K shares. The average number of MRSN shares traded daily for last 3 months was 1.24M.
The market value of MRSN currently stands at $193.83M with its latest stock price at $1.58 and 122.68M of its shares outstanding.